retatrutide phase 2 trial type 2 diabetes results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 More data on Retatrutide dropped

No oversimplifications

Both doses significantly outperformed the placebo across all measured outcomes

Can I microdose

Initial results indicate that when comparing tirzepatide vs retatrutide, Retatrutide may lead to more substantial reductions in body mass, improving its efficacy in addressing obesity

Semaglutide (Wegovy, Ozempic) Half-life: ~7 days Dosing: Once weekly subcutaneous injection Profile: Provides steady appetite suppression and glycemic control

As weight-loss drugs, some members of this class may promote the shedding of more than Researchers studying GLP-1 found that the hormone has receptors and effects outside the gut